Literature DB >> 11005811

Mapping the binding site of colchicinoids on beta -tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354.

R Bai1, D G Covell, X F Pei, J B Ewell, N Y Nguyen, A Brossi, E Hamel.   

Abstract

2-Chloroacetyl-2-demethylthiocolchicine (2CTC) and 3-chloroacetyl-3-demethylthiocolchicine (3CTC) resemble colchicine in binding to tubulin and react covalently with beta-tubulin, forming adducts with cysteine residues 239 and 354. The adducts at Cys-239 are less stable than those at Cys-354 during formic acid digestion. Extrapolating to zero time, the Cys-239 to Cys-354 adduct ratio is 77:23 for 2CTC and 27:73 for 3CTC. Using energy minimization modeling to dock colchicinoids into the electron crystallographic model of beta-tubulin in protofilaments (Nogales, E. , Wolf, S. G., and Downing, K. H. (1998) Nature 391, 199-203), we found two potential binding sites. At one, entirely encompassed within beta-tubulin, the C2- and C3-oxygen atoms of 2CTC and 3CTC overlapped poorly with those of colchicine and thiocolchicine, but distances from the reactive carbon atoms of the analogs to the sulfur atoms of the cysteine residues were qualitatively consistent with reactivity. The other potential binding site was located at the alpha/beta interface. Here, the oxygen atoms of the analogs overlapped well with those of colchicine, but relative distances of the reactive carbons to the cysteine sulfur atoms did not correlate with the observed reactivity. A significant conformational change must occur in the colchicine binding site of tubulin in the transition from the unpolymerized to the polymerized state.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005811     DOI: 10.1074/jbc.M005299200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Cyclostreptin derivatives specifically target cellular tubulin and further map the paclitaxel site.

Authors:  Enrique Calvo; Isabel Barasoain; Ruth Matesanz; Benet Pera; Emilio Camafeita; Oriol Pineda; Ernest Hamel; Christopher D Vanderwal; José Manuel Andreu; Juan A López; José Fernando Díaz
Journal:  Biochemistry       Date:  2011-12-30       Impact factor: 3.162

2.  Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers.

Authors:  Pascale Barbier; Audrey Dorléans; Francois Devred; Laura Sanz; Diane Allegro; Carlos Alfonso; Marcel Knossow; Vincent Peyrot; Jose M Andreu
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

Review 3.  An overview of tubulin inhibitors that interact with the colchicine binding site.

Authors:  Yan Lu; Jianjun Chen; Min Xiao; Wei Li; Duane D Miller
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

Review 4.  The molecular basis that unifies the metabolism, cellular uptake and chemopreventive activities of dietary isothiocyanates.

Authors:  Yuesheng Zhang
Journal:  Carcinogenesis       Date:  2011-11-10       Impact factor: 4.944

5.  Allyl isothiocyanate arrests cancer cells in mitosis, and mitotic arrest in turn leads to apoptosis via Bcl-2 protein phosphorylation.

Authors:  Feng Geng; Li Tang; Yun Li; Lu Yang; Kyoung-Soo Choi; A Latif Kazim; Yuesheng Zhang
Journal:  J Biol Chem       Date:  2011-07-21       Impact factor: 5.157

6.  Allocolchicinoids bearing a Michael acceptor fragment for possible irreversible binding of tubulin.

Authors:  Ekaterina S Sazanova; Iuliia A Gracheva; Diane Allegro; Pascale Barbier; Sébastien Combes; Elena V Svirshchevskaya; Alexey Yu Fedorov
Journal:  RSC Med Chem       Date:  2020-06-04

7.  Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.

Authors:  Weiwei Wang; Hangxiao Zhang; Xumin Wang; Jordan Patterson; Philip Winter; Kathryn Graham; Sunita Ghosh; John C Lee; Christos D Katsetos; John R Mackey; Jack A Tuszynski; Gane Ka-Shu Wong; Richard F Ludueña
Journal:  Protoplasma       Date:  2016-12-09       Impact factor: 3.356

8.  Molecular basis for fungal selectivity of novel antimitotic compounds.

Authors:  Thomas Lila; Thomas E Renau; Lori Wilson; Jay Philips; Georges Natsoulis; M Jamie Cope; William J Watkins; Jerry Buysse
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity.

Authors:  Ashutosh Tripathi; Micaela Fornabaio; Glen E Kellogg; John T Gupton; David A Gewirtz; W Andrew Yeudall; Nina E Vega; Susan L Mooberry
Journal:  Bioorg Med Chem       Date:  2007-12-04       Impact factor: 3.641

10.  Applying an empirical hydropathic forcefield in refinement may improve low-resolution protein X-ray crystal structures.

Authors:  Vishal N Koparde; J Neel Scarsdale; Glen E Kellogg
Journal:  PLoS One       Date:  2011-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.